Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial

Pfizer has unveiled positive results from a Phase 3 trial evaluating Sutent as adjuvant therapy in patients at high risk of recurrent renal cell carcinoma after surgery.

The tyrosine kinase inhibitor reached its primary endpoint of prolonging disease-free survival in the adjuvant setting compared to placebo.

The treatment was approved in 2006 in the U.S. for the treatment of advanced RCC.